{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:08:12Z","timestamp":1787069292763,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Research and Development and Promotion Project of Henan Province","award":["252102311285"],"award-info":[{"award-number":["252102311285"]}]},{"name":"Key Research and Development and Promotion Project of Henan Province","award":["232102310425"],"award-info":[{"award-number":["232102310425"]}]},{"name":"Research Projects of Higher Education Institutions in Henan Province","award":["25B360015"],"award-info":[{"award-number":["25B360015"]}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["252300420157"],"award-info":[{"award-number":["252300420157"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12012-026-10169-w","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T06:21:59Z","timestamp":1786170119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salidroside Alleviates Mobocertinib-Induced Cardiotoxicity by Improving Cardiac Electrophysiology"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4025-0077","authenticated-orcid":false,"given":"Chi","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayan","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"issue":"5","key":"10169_CR1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/ijms26052049","volume":"26","author":"B Smolarz","year":"2025","unstructured":"Smolarz, B., \u0141ukasiewicz, H., Samulak, D., Piekarska, E., Ko\u0142aci\u0144ski, R., & Romanowicz, H. (2025). Lung cancer-epidemiology, pathogenesis, treatment and molecular aspect (review of literature). International Journal of Molecular Sciences, 26(5), 2049. https:\/\/doi.org\/10.3390\/ijms26052049","journal-title":"International Journal of Molecular Sciences"},{"key":"10169_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369356","volume":"15","author":"P Pandya","year":"2024","unstructured":"Pandya, P., Al-Qasrawi, D. S., Klinge, S., & Justilien, V. (2024). Extracellular vesicles in non-small cell lung cancer stemness and clinical applications. Frontiers in Immunology, 15, Article 1369356. https:\/\/doi.org\/10.3389\/fimmu.2024.1369356","journal-title":"Frontiers in Immunology"},{"key":"10169_CR3","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.62347\/wtmu5537","volume":"15","author":"C Yuan","year":"2025","unstructured":"Yuan, C., Yu, J. Y., Zeng, C. X., Wang, M. C., Zhang, S., Huang, Y. B., Yu, X. S., Kong, F. M., & Chen, L. W. (2025). New advances in the treatment of EGFR exon20ins mutant advanced NSCLC. American Journal of Cancer Research, 15, 1852\u20131873. https:\/\/doi.org\/10.62347\/wtmu5537","journal-title":"American Journal of Cancer Research"},{"key":"10169_CR4","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s40265-021-01632-9","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. (2021). Mobocertinib: First approval. Drugs, 81, 2069\u20132074. https:\/\/doi.org\/10.1007\/s40265-021-01632-9","journal-title":"Drugs"},{"key":"10169_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4761","volume":"7","author":"C Zhou","year":"2021","unstructured":"Zhou, C., Ramalingam, S. S., Kim, T. M., Kim, S. W., Yang, J. C., Riely, G. J., Mekhail, T., Nguyen, D., Garcia Campelo, M. R., Felip, E., Vincent, S., Jin, S., Griffin, C., Bunn, V., Lin, J., Lin, H. M., Mehta, M., & J\u00e4nne, P. A. (2021). Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR Exon 20 insertion-positive metastatic non-small cell lung cancer: A phase 1\/2 open-label nonrandomized clinical trial. JAMA Oncology, 7, Article e214761. https:\/\/doi.org\/10.1001\/jamaoncol.2021.4761","journal-title":"JAMA Oncology"},{"key":"10169_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/1078-0432.Ccr-22-2072","volume":"29","author":"ES Duke","year":"2023","unstructured":"Duke, E. S., Stapleford, L., Drezner, N., Amatya, A. K., Mishra-Kalyani, P. S., Shen, Y. L., Maxfield, K., Zirkelbach, J. F., Bi, Y., Liu, J., Zhang, X., Wang, H., Yang, Y., Zheng, N., Reece, K., Wearne, E., Glen, J. J., Ojofeitimi, I., Scepura, B., \u2026 Donoghue, M. (2023). FDA approval summary: Mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. Clinical Cancer Research, 29, 508\u2013512. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-2072","journal-title":"Clinical Cancer Research"},{"key":"10169_CR7","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1111\/bcp.15030","volume":"88","author":"TE Eroglu","year":"2022","unstructured":"Eroglu, T. E., Barcella, C. A., Blom, M. T., Mohr, G. H., Souverein, P. C., Torp-Pedersen, C., Folke, F., Wissenberg, M., de Boer, A., Schwartz, P. J., Gislason, G. H., & Tan, H. L. (2022). Out-of-hospital cardiac arrest and differential risk of cardiac and non-cardiac QT-prolonging drugs in 37 000 cases. British Journal of Clinical Pharmacology, 88, 820\u2013829. https:\/\/doi.org\/10.1111\/bcp.15030","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10169_CR8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27833","author":"SS Kahlon","year":"2022","unstructured":"Kahlon, S. S., Sikandar, R., Tejovath, S., Nair, S., Hassan, D., Patel, K. K., Peddemul, A., & Mostafa, J. A. (2022). Diagnosing Torsades De pointes based on correlation to QT interval: A systematic review. Cureus. https:\/\/doi.org\/10.7759\/cureus.27833","journal-title":"Cureus"},{"key":"10169_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152460","volume":"780","author":"YF Zhou","year":"2025","unstructured":"Zhou, Y. F., Wang, G. X., Yang, R. N., Qi, H., Fan, Y. Y., Li, W. Y., Zhao, G. A., Hao, G. L., Lin, F., & Chen, Z. G. (2025). Electrophysiological consequences of acute mobocertinib exposure in isolated rat and guinea-pig hearts and transfected cell lines. Biochemical and Biophysical Research Communications, 780, Article 152460. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152460","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10169_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2024.153830","volume":"505","author":"W Wu","year":"2024","unstructured":"Wu, W., Sun, J., Zhang, J., Zhao, H., Qiu, S., Li, C., Shi, C., & Xu, Y. (2024). Phosphoproteomics reveals a novel mechanism underlying the proarrhythmic effects of nilotinib, vandetanib, and mobocertinib. Toxicology, 505, Article 153830. https:\/\/doi.org\/10.1016\/j.tox.2024.153830","journal-title":"Toxicology"},{"key":"10169_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1309598","volume":"14","author":"Q Liu","year":"2023","unstructured":"Liu, Q., Chen, J., Zeng, A., & Song, L. (2023). Pharmacological functions of salidroside in renal diseases: Facts and perspectives. Frontiers in Pharmacology, 14, Article 1309598. https:\/\/doi.org\/10.3389\/fphar.2023.1309598","journal-title":"Frontiers in Pharmacology"},{"key":"10169_CR12","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1002\/fsn3.2459","volume":"9","author":"Y Xiong","year":"2021","unstructured":"Xiong, Y., Wang, Y., Xiong, Y., & Teng, L. (2021). Protective effect of salidroside on hypoxia-related liver oxidative stress and inflammation via Nrf2 and JAK2\/STAT3 signaling pathways. Food Science & Nutrition, 9, 5060\u20135069. https:\/\/doi.org\/10.1002\/fsn3.2459","journal-title":"Food Science & Nutrition"},{"key":"10169_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s10557-020-07072-z","volume":"35","author":"YW Hsiao","year":"2021","unstructured":"Hsiao, Y. W., Tsai, Y. N., Huang, Y. T., Liu, S. H., Lin, Y. J., Lo, L. W., Hu, Y. F., Chung, F. P., Lin, S. F., Chang, S. L., Higa, S., & Chen, S. A. (2021). Rhodiola crenulata reduces ventricular arrhythmia through mitigating the activation of IL-17 and inhibiting the MAPK signaling pathway. Cardiovascular Drugs and Therapy, 35, 889\u2013900. https:\/\/doi.org\/10.1007\/s10557-020-07072-z","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10169_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113196","volume":"142","author":"W Ren","year":"2024","unstructured":"Ren, W., Huang, Y., Meng, S., Cao, Z., Qin, N., Zhao, J., Huang, T., Guo, X., Chen, X., Zhou, Z., Zhu, Y., Yu, L., & Wang, H. (2024). Salidroside treatment decreases the susceptibility of atrial fibrillation in diabetic mice by reducing mTOR-STAT3-MCP-1 signaling and atrial inflammation. International Immunopharmacology, 142, Article 113196. https:\/\/doi.org\/10.1016\/j.intimp.2024.113196","journal-title":"International Immunopharmacology"},{"key":"10169_CR15","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/cpdd.951","volume":"10","author":"S Zhang","year":"2021","unstructured":"Zhang, S., Jin, S., Griffin, C., Feng, Z., Lin, J., Baratta, M., Brake, R., Venkatakrishnan, K., & Gupta, N. (2021). Single-dose pharmacokinetics and tolerability of the oral epidermal growth factor receptor inhibitor mobocertinib (TAK-788) in healthy volunteers: Low-fat meal effect and relative bioavailability of 2 capsule products. Clinical Pharmacology in Drug Development, 10, 1028\u20131043. https:\/\/doi.org\/10.1002\/cpdd.951","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"10169_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/fjc.0000000000000009","volume":"62","author":"XL Wang","year":"2013","unstructured":"Wang, X. L., Wang, X., Xiong, L. L., Zhu, Y., Chen, H. L., Chen, J. X., Wang, X. X., Li, R. L., Guo, Z. Y., Li, P., & Jiang, W. (2013). Salidroside improves doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis. Journal of Cardiovascular Pharmacology, 62, 512\u2013523. https:\/\/doi.org\/10.1097\/fjc.0000000000000009","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10169_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12265-020-10056-x","volume":"14","author":"F Yan","year":"2021","unstructured":"Yan, F., Liu, R., Zhuang, X., Li, R., Shi, H., & Gao, X. (2021). Salidroside attenuates doxorubicin-induced cardiac dysfunction partially through activation of QKI\/FoxO1 pathway. Journal of Cardiovascular Translational Research, 14, 355\u2013364. https:\/\/doi.org\/10.1007\/s12265-020-10056-x","journal-title":"Journal of Cardiovascular Translational Research"},{"key":"10169_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3892\/br.2024.1868","volume":"21","author":"W Zhang","year":"2024","unstructured":"Zhang, W., Liao, Z., Xu, C., & Lin, X. (2024). Salidroside rescues hypoxic cardiomyocytes by regulating the EGLN1\/HIF-1\u03b1 pathway. Biomedical Reports, 21, 180. https:\/\/doi.org\/10.3892\/br.2024.1868","journal-title":"Biomedical Reports"},{"key":"10169_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3724\/abbs.2024199","volume":"57","author":"B Li","year":"2025","unstructured":"Li, B., Zhang, X., Sun, F., Zhang, X., Liu, H., & Zhang, S. (2025). Validation of six commercially available angiotensin II type 1 receptor antibodies. Acta Biochimica et Biophysica Sinica (Shanghai), 57, 851\u2013855. https:\/\/doi.org\/10.3724\/abbs.2024199","journal-title":"Acta Biochimica et Biophysica Sinica (Shanghai)"},{"issue":"7","key":"10169_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3390\/cimb47070501","volume":"47","author":"U Bayraktutan","year":"2025","unstructured":"Bayraktutan, U. (2025). Angiotensin II and cardiovascular disease: Balancing pathogenic and protective pathways. Current Issues in Molecular Biology, 47(7), 501. https:\/\/doi.org\/10.3390\/cimb47070501","journal-title":"Current Issues in Molecular Biology"},{"key":"10169_CR21","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1111\/bph.12959","volume":"172","author":"J Inserte","year":"2015","unstructured":"Inserte, J., & Garcia-Dorado, D. (2015). The cGMP\/PKG pathway as a common mediator of cardioprotection: Translatability and mechanism. British Journal of Pharmacology, 172, 1996\u20132009. https:\/\/doi.org\/10.1111\/bph.12959","journal-title":"British Journal of Pharmacology"},{"issue":"13","key":"10169_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136361","volume":"26","author":"S Thatcher","year":"2025","unstructured":"Thatcher, S., Khalid, A., Ahmed, A. B., Gill, R., & Kia, A. (2025). PDE9A promotes calcium-handling dysfunction in right heart failure via cGMP-PKG pathway suppression: A mechanistic and therapeutic review. International Journal of Molecular Sciences, 26(13), Article 6361. https:\/\/doi.org\/10.3390\/ijms26136361","journal-title":"International Journal of Molecular Sciences"},{"issue":"23","key":"10169_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237305","volume":"26","author":"NF Sangweni","year":"2021","unstructured":"Sangweni, N. F., Dludla, P. V., Chellan, N., Mabasa, L., Sharma, J. R., & Johnson, R. (2021). The implication of low dose dimethyl sulfoxide on mitochondrial function and oxidative damage in cultured cardiac and cancer cells. Molecules, 26(23), Article 7305. https:\/\/doi.org\/10.3390\/molecules26237305","journal-title":"Molecules"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10169-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10169-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10169-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:19:19Z","timestamp":1787066359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-026-10169-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10169"],"URL":"https:\/\/doi.org\/10.1007\/s12012-026-10169-w","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"92"}}